GlaxoSmithKline
GSK • XNYS
GlaxoSmithKline is a publicly traded company trading on XNYS, led by CEO Luke Victor Miels.
CEOLuke Victor Miels
Next Earnings
Upcoming earnings announcement for GlaxoSmithKline
Date
Wednesday, April 29, 2026 (in 4 weeks)
Timing
Before Market Open (3:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
$1.18
Revenue Estimate
$10.2B
Earnings History
Past 12 earnings reports for GlaxoSmithKline
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 4, 2026 | Q4 2025 | $0.68Est: $0.64 | +6.3% | $11.5BEst: $11.2B | +2.4% | — |
| Oct 29, 2025 | Q3 2025 | $1.48Est: $1.26 | +17.8% | $11.5BEst: $11.2B | +3.3% | — |
| Jul 30, 2025 | Q2 2025 | $1.24Est: $1.12 | +10.8% | $10.7BEst: $10.3B | +3.2% | — |
| Apr 30, 2025 | Q1 2025 | $1.13Est: $1.04 | +8.7% | $9.5BEst: $7.5B | +26.8% | — |
| Feb 5, 2025 | Q4 2024 | $0.58Est: $0.43 | +34.9% | $10.1BEst: $9.6B | +5.2% | — |
| Oct 30, 2024 | Q3 2024 | $1.29Est: $1.23 | +4.9% | $10.4BEst: $10.8B | -3.4% | — |
| Jul 31, 2024 | Q2 2024 | $1.10Est: $0.99 | +11.1% | $9.9BEst: $9.7B | +2.5% | — |
| May 1, 2024 | Q1 2024 | $1.09Est: $0.91 | +20.1% | $9.3BEst: $8.9B | +4.7% | — |
| Jan 31, 2024 | Q4 2023 | $0.72Est: $0.75 | -4.3% | $10.1BEst: $9.6B | +4.7% | — |
| Nov 1, 2023 | Q3 2023 | $1.27Est: $1.07 | +18.7% | $10.3BEst: $9.4B | +9.6% | — |
| Jul 26, 2023 | Q2 2023 | $0.97Est: $0.87 | +11.5% | $9.0BEst: $9.0B | +0.0% | — |
| Apr 26, 2023 | Q1 2023 | $0.90Est: $0.82 | +9.8% | $8.4BEst: $8.1B | +4.8% | — |